Get started
CATALYST PHARMACEUCATALYST PHARMACEUCATALYST PHARMACEU

CATALYST PHARMACEU

No trades
See on Supercharts
Overview
Financials News Ideas Forecast

CN2 chart

Upcoming earnings

Next report date
Report period
Q1 2024
EPS estimate
0.18CHF
Revenue estimate
‪89.11 M‬CHF

Key stats

Market capitalization
‪1.60 B‬CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
26.214
Basic EPS (TTM)
0.567CHF
Net income (FY)
‪60.12 M‬CHF
Revenue (FY)
‪335.26 M‬CHF
Shares float
‪101.44 M‬
Beta (1Y)
1.15

About Catalyst Pharmaceuticals, Inc.

Sector
Health Technology
CEO
Richard John Daly
Headquarters
Coral Gables
Website
catalystpharma.com
Employees (FY)
167
Founded
2002
FIGI
BBG00LVDFHG9
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of CN2 is 14.935 CHF — it has increased by 2.36% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange CATALYST PHARMACEU stocks are traded under the ticker CN2.
CATALYST PHARMACEU is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
CN2 stock is 2.31% volatile and has beta coefficient of 1.15. Check out the list of the most volatile stocks — is CATALYST PHARMACEU there?
CN2 earnings for the last quarter are −0.27 CHF per share, whereas the estimation was −0.27 CHF resulting in a 3.33% surprise. The estimated earnings for the next quarter are 0.22 CHF per share. See more details about CATALYST PHARMACEU earnings.
CATALYST PHARMACEU revenue for the last quarter amounts to ‪93.95 M‬ CHF despite the estimated figure of ‪91.89 M‬ CHF. In the next quarter revenue is expected to reach ‪89.19 M‬ CHF.
Yes, you can track CATALYST PHARMACEU financials in yearly and quarterly reports right on TradingView.
CN2 stock hasn't changed in a week, the last month showed zero change in price, over the last year CATALYST PHARMACEU has showed a 2.36% increase.
CN2 net income for the last quarter is ‪29.34 M‬ CHF, while the quarter before that showed ‪−28.16 M‬ CHF of net income which accounts for 204.16% change. Track more CATALYST PHARMACEU financial stats to get the full picture.
Today CATALYST PHARMACEU has the market capitalization of ‪1.60 B‬, it has increased by 17.14% over the last week.
No, CN2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CN2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CATALYST PHARMACEU stock right from TradingView charts — choose your broker and connect to your account.
CN2 reached its all-time high on Dec 21, 2022 with the price of 17.432 CHF, and its all-time low was 14.590 CHF and was reached on Jan 27, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 27, 2024, the company has 167.00 employees. See our rating of the largest employees — is CATALYST PHARMACEU on this list?
We've gathered analysts' opinions on CATALYST PHARMACEU future price: according to them, CN2 price has a max estimate of 31.10 CHF and a min estimate of 20.12 CHF. Read a more detailed CATALYST PHARMACEU forecast: see what analysts think of CATALYST PHARMACEU and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CATALYST PHARMACEU EBITDA is ‪100.94 M‬ CHF, and current EBITDA margin is 30.12%. See more stats in CATALYST PHARMACEU financial statements.